Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers

Pharmacology

Volumn 88, Issue 5-6, 2011, Pages 288-294

  Xue, Ling ^a   Zhang, Hua ^a   Ma, Sheng ^a   Rui, Jian Zhong ^b   Miao, Li Yan ^a  

^a SOOCHOW UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Healthy volunteers; Pharmacogenetics; Population pharmacokinetics; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS;

ADULT; ARTICLE; CHINESE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BODY SURFACE AREA; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; ERYTHROCYTE COUNT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TACROLIMUS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 80755129370     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000331856     Document Type: Article

References (25)

1. Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-653. (Pubitemid 38981845)
2. Jacobson P, Uberti J, Davis W, Ratanatharathorn V: Tacrolimus: A new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 217-225. (Pubitemid 28382985)
3. Przepiorka D, Devine S, Fay J, Uberti J, Wingard J: Practical considerations in the using of tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant 1999; 24: 1053-1056.
4. Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ: Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 161-167. (Pubitemid 30496962)
5. Wallin JE, Friberg LE, Fasth A, Staatz CE: Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: New initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit 2009; 31: 457-466.
6. Musuamba FT, Mourad M, Haufroid V, Delattre IK, Verbeeck RK, Wallemacq P: Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: A population pharmacokinetic study. Ther Drug Monit 2009; 31: 734-742.
7. Boswell GW, Bekersky I, Fay J, Wingard J, Antin J, Weisdorf D, Maher R, Fitzsimmons W, Nash R: Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 1998; 21: 23-28. (Pubitemid 28043432)
8. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K: Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 2007; 64: 185-191. (Pubitemid 47063248)
9. Wang S, Magill JE, Vicente FB: A fast and simple high-performance liquid chromatography/ mass spectrometry method for simultaneous measurement of whole blood tacrolimus and sirolimus. Arch Pathol Lab Med 2005; 129: 661-665. (Pubitemid 40616971)
10. Taylor PJ, Salm P, Lynch SV, Pillans PI: Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2000; 22: 608-612.
11. Streit F, Armstrong VW, Oellerich M: Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem 2002; 48: 955-958. (Pubitemid 34587603)
12. Park K, Kim YS, Kwon KI, Park MS, Lee YJ, Kim KH: A randomized, open-label, twoperiod, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther 2007; 29: 154-162. (Pubitemid 46414035)
13. Miao LY, Huang CR, Hou JQ, Qian MY: Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2008; 29: 1-5.
14. Brendel K, Dartois C, Comets E, Lemenuel- Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentré F: Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46: 221-234. (Pubitemid 46425648)
15. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T: Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 2005; 24: 465-475. (Pubitemid 40387260)
16. Post TM, Freijer JI, Ploeger BA, Danhof M: Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008; 35: 185-202.
17. Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL: Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 2007; 32: 505-515. (Pubitemid 47404287)
18. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S: Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007; 64: 750-757. (Pubitemid 350222052)
19. Zahir H, McLachlan AJ, Nelson A, McCauhan G, Gleeson M, Akhlaghi F: Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 2005; 27: 422-430. (Pubitemid 41098815)
20. Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ: Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009; 31: 187-197.
21. Staatz CE, Goodman LK, Tett SE: Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors. Part I. Clin Pharmacokinet 2010; 49: 141-175.
22. Wallemacq PE, Verbeeck RK: Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40: 283-295. (Pubitemid 32458154)
23. Qiu XH, Zhang Y, Shen ZY, Rui JZ, Li JH: Population pharmacokinetics of tacrolimus in 22 Chinese recipients of liver transplantation. J Med Postgrad 2008; 21: 915-919.
24. Op den Buijscha RA, Christiaans MH, Stolkc LM, de Vries LE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O: Tacrolimus pharmacokinetics and pharmacogenetics: Influence of adenosine triphosphate- binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007; 21: 427-435. (Pubitemid 47084029)
25. Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY: Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther 2007; 32: 89-95. (Pubitemid 46213944)